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The ability of immunotherapy with heat-killed Mycobacterium vaccae (NCTC 11659), as an addition to the
available chemotherapy, to improve the outcome in patients with multi-drug-resistant tubercle bacilli (MDRTB)
who had not been cured by chemotherapy alone was evaluated in tuberculosis centres in Estonia, Iran, Kuwait,
New Zealand, Romania, Vietnam and the U.K.
A total of 337 patients in the above countries received intradermal injections of M. vaccae in addition to
chemotherapy. Patients were grouped according to the length of their histories of disease: less than or greater than 2
years duration. Initially, single doses ofM. vaccae were given but subsequently up to 12 doses at 2-month intervals
were given. Chemotherapy varied from isoniazid alone to drugs selected according to susceptibility tests. Most
patients had failed to respond to repeated courses of chemotherapy and the majority were expected to die from their
disease. Results were assessed by sputum smear and culture and by clinical observations. Cured patients were
followed for 18–24 months to exclude relapse.
Eighteen of 22 (82%) patients with disease for less than 2 years were bacteriologically cured by one or two doses
of M. vaccae. Among 315 chronic patients, 24 (7?6%) were cured after one dose, 37?9% after seven doses and
41?6% after 12 doses. Sixty-six chronic patients were lost to follow-up, or died, during the multi-dose regimens.
Nine of 33 patients (27%) with advanced disease unaffected by several courses of chemotherapy and discharged on
isoniazid alone in Vietnam were cured by 3–12 injections of M. vaccae.
The data provide preliminary evidence that the addition of immunotherapy with M. vaccae to chemotherapy
improves the rate of cure of MDRTB, most effectively in patients with short histories of disease, but multiple dosing
can have beneficial effects in chronic patients in whom chemotherapy has failed. A randomized clinical trial of this
immunotherapy in MDRTB patients is therefore required.
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The treatment of tuberculosis caused by multi-drug-
resistant tubercle bacilli (MDRTB), defined as resistant to
isoniazid and rifampicin, with or without resistance to
other drugs, remains a major problem, especially in the
former USSR and the developing world (l). EffectiveReceived 9 January 2001 and accepted 12 February 2001.
Correspondence should be addressed to: John L. Stanford, M. D.,
Department of Medical Microbiology, Windeyer Institute of
Medical Sciences, Royal Free and University College Medical
School, 46 Cleveland Street, London WIT 4JF, U.K. Fax: +44
207-636-817; E-mail: j.stanford@ucl.ac.uk
0954-6111/01/060444+04 $35?00/0management of MDRTB requires high quality laboratory
support and individualized, fully supervised, therapy
(2,3), but resources for such interventions are rarely
encountered in the developing nations where the
mortality rate of MDRTB is extremely high. Novel
approaches to the therapy of MDRTB are urgently
required, such as a combination of chemotherapy and
immunotherapy (4). We have added from one to 12 doses of
an immunotherapeutic agent based on heat-killed Myco-
bacterium vaccae (NCTC 11659) to the treatment of
patients with different degrees of chronicity, receiving a
variety of drug regimens.
Most previous studies of immunotherapy withM. vaccae
in tuberculosis have been of single doses given early in the
course of chemotherapy for newly diagnosed cases of
predominantly drug susceptible disease (5–7). Two recently# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Numbers of doses of M. vaccae after which
patients with chronic MDRTB became bacteriologically
cured
Number of doses
of immunotherapy
Proportion
cured after
each dose
Cumulative numbers
and percentage
cured
1 24/315 (7?6%) 24 (7?6%)
2 18/193 (9?3%) 42 (16?9%)
3 14/164 (8?5%) 56 (17?8%)
4 15/129 (11?6%) 71 (19?2%)
5 9/92 (9?8%) 80 (29%)
6 1/36 (2?8%) 81 (31?8%)
7 2/33 (6?1%) 83 (37?9%)
8–12 1/27 (3?7%) 84 (41?6%)
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yielded disparate results. The study from South Africa
showed no effect (8), and results from Uganda showed
faster clearance of tubercle bacilli from the sputum 1 month
after starting chemotherapy, and significantly improved
clearance of lesions on chest X-ray at the end of
chemotherapy and 6 months later, in the immunotherapy
group (9).
It was a conclusion of the Uganda trial that a study
of multiple injections of M. vaccae in the treatment
of MDRTB should be carried out and the current paper
reports the data already available on this subject.
Materials and methods
PATIENTS
Four patients in Estonia, 109 in India, 41 in Iran, two in
Kuwait, two in New Zealand, 19 in Romania, 129 in
Vietnam and 31 in the U.K. have been studied. All had
MDRTB confirmed by drug susceptibility testing, accord-
ing to the methods used by the reference laboratories in the
respective countries. Patients were divided according to the
length of their histories of tuberculosis. Twenty-two
patients had developed tuberculosis during the preceding
2 years, many with initial multi-drug resistance. The
remaining 315 patients had chronic disease, with histories
of tuberculosis varying from 2 years to 11 years. Most of
these had received repeated courses of treatment but had
not been cured.
CHEMOTHERAPY
Patients received a variety of regimens depending on the
drugs available and national treatment policies. Three
patients with short histories were receiving standard first-
line anti-tuberculosis chemotherapy, 142 (including five
with short histories) were on re-treatment regimens, 79
(including 14 with short histories) were receiving regimens
tailored to the resistance patterns of their infecting
organisms and 113 chronic patients were receiving
5mgkg71 daily isoniazid alone. Despite these various
treatments, the great majority of chronic patients entering
our study were those who had failed to be cured by these
chemotherapeutic regimens.
IMMUNOTHERAPY
Heat-killed M. vaccae NCTC 11659 in borate buffered
saline, pH 8, was used. Treatment consisted of intradermal
injections over a deltoid muscle of 0?1ml containing
1mg wet weight of bacilli. Three recent and 96 chronic
cases, of whom 80 were receiving isoniazid alone, entered
studies in which only one immunotherapeutic injection was
given. Up to four doses were given to 41 patients in Iran,
including five recent cases. Up to five doses were given to 85
patients with chronic disease in Vietnam and up to seven
doses were given to 29 similar patients in India. In themost recent studies, up to 12 injections have been given
to 83 patients, including 14 recent cases, in several
countries. The reagent has an excellent safety record and
reactions to the twelfth dose were no different from those to
the first.
FOLLOW-UP AND OBSERVATIONS
Follow-up after immunotherapy was by clinical examina-
tion and sputum smear microscopy for acid-fast bacilli.
Apparent bacteriological cures were confirmed by culture
and, in almost all cases, by subsequent follow-up for 18–24
months.
Results
The proportion and cumulative numbers of patients cured
bacteriologically after each injection of M. vaccae are
shown in Table 1.
PATIENTS WITH SHORT HISTORIES OF
DISEASE (2 YEARS OR LESS)
Fourteen of the 22 patients with short histories of disease
(2 years or less) became sputum culture-negative after a
single dose of SRL 172; four more became negative after
a second dose given 2 months later and one patient
became negative after seven doses given at 2-month
intervals. One patient was lost to follow-up after a
single dose and two died, despite receiving two and five
doses of immunotherapy, respectively. Eight patients
received standard or failure/relapse chemotherapy regimens
and seven of these were cured; 14 received chemotherapy
tailored to their drug susceptibility pattern and 12 were
cured.
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(HISTORIES OF 2 YEARS OR MORE)
After a single dose of M. vaccae many of the 315 patients
with chronic disease became temporarily sputum smear-
negative but 24 became sustainedly culture-negative. After
a second dose given 2–6 months later 18 additional patients
became culture-negative. Increasing the number of doses
given at 2-month intervals led to 38 more patients becoming
culture-negative after five doses and an additional four
patients receiving up to 10 doses were also cured. Twenty-six
sputum-positive patients went on to receive 12 doses, but
without achieving bacteriological cure. During the study, 66
patients with chronic disease either died or were lost to
follow-up whilst still sputum-positive for tubercle bacilli.
None of the 80 Indian patients receiving isoniazid alone
and a single injection of M. vaccae achieved bacteriological
cure but nine of the 33 Vietnamese receiving isoniazid
monotherapy plus up to 12 doses of M. vaccae were cured:
two after three doses; five after five doses; one after six
doses and one after seven doses. Among the patients
receiving failure/relapse regimens: 32 of 137 (23%) were
cured: 12 after a single injection; two more after a second
injection and a further 18 after three to five injections. The
best results were obtained in the 65 patients who received
chemotherapy tailored to their drug susceptibility patterns:
43 (66%) achieving bacteriological cure after one to 10
injections of M. vaccae.
For chronic patients the combination of chemotherapy
tailored to the drug susceptibility pattern of the infecting
bacilli with multiple-dosing with immunotherapy produces
the best results (Table 2). Thus, none of the 80 patients
receiving isoniazid alone and a single dose of M. vaccae
were cured but nine of a further 33 patients receiving
isoniazid alone were cured after multiple doses; 12 of 137
(8?8%) receiving treatment-failure/relapse chemotherapy
were cured after one dose of M. vaccae and 12 of 65
(18?5%) receiving chemotherapy tailored to their pattern of
drug susceptibility were cured after one dose of M. vaccae.
Better bacteriological cure rates were observed in patientsTABLE 2. Bacteriological cures achieved in patients with
chronic tuberculosis according to chemotherapy regimen
and number of doses (single or multiple) of immunother-
apy*
Type of therapy Single-dose
M. vaccae
Multiple-dose
M. vaccae
Isoniazid alone 0/80 P50?001 9/33 (27%)
P=0?005 P=0?38
Re-treatment
regimen
12/137 (8?8%) P=0?13 20/120 (17%)
P=0?13 P=0?0002
Tailored therapy 12/65 (18.5%) P=0?004 31/53 (58%)
*Statistical analysis by Chi-squared test with Yates’
correction or Fishers exact test, as appropriate, using
EPI-INFO 6.in these three treatment categories who received multiple
doses of immunotherapy. Thus, nine of 33 (27?3%) receiv-
ing isoniazid alone, 21 of 121 (17?4%) receiving treatment-
failure/relapse chemotherapy and 43 of 65 (66?2%) receiv-
ing tailored chemotherapy. These figures do not take into
account the 36% of patients lost to follow-up, or dying
before all the available doses of M. vaccae had been given.
Discussion
The series of small pilot studies presented here have many
weaknesses, not least the fact that they were not controlled
with placebo recipients. Their purpose was to determine
whether anything could be achieved by the addition of
immunotherapy and whether a prospective, randomized,
placebo-controlled, trial was justified.
Notwithstanding, they give an insight of what might be
achievable. Eleven successful cures out of 41 patients in
Iran with up to four doses of M. vaccae can be compared
with the historical control of no more than one in 100 such
patients cured with the same drug regimens over the
previous 2 years (5,6). In Vietnam, cure was achieved in 14
of 85 chronic patients receiving up to five doses of
M. vaccae during their second or third course of the re-
treatment regimen that had failed to cure them on previous
occasions. Also, in Vietnam, nine of 33 patients who were
sent home on isoniazid monotherapy and were given up to
12 doses of M. vaccae were successfully cured. These both
indicate important treatment benefits (these groups are
included but not distinguished in Table 2).
As expected, patients with short histories (less than 2
years) responded much better to the immunotherapy than
did chronic cases. Those with short histories are likely to
have less lung damage and fibrosis and the proportion of
intracellular bacilli is likely to be relatively high. Thus, 19 of
these 22 patients were cured, all but one after only one or
two doses of M. vaccae, which is better than has been
recorded for the use of chemotherapy alone, even where
surgical resection has been available (7).
Analysis of the results for chronic patients was compli-
cated by the different chemotherapy regimens they were
receiving, even though these had been found unsuccessful in
the majority of those entering our studies. In most places,
the patients were those who had problems with adherence
to treatment and who were generally considered untrea-
table. The studies were also complicated by the varying
dosage schedules of immunotherapy offered to them. As
shown in Table 2, the outcome is related to the expected
effectiveness of the drug regimen but in all cases the
outcome was significantly better in patients receiving
multiple doses of immunotherapy. This is even the case in
patients receiving isoniazid monotherapy that would be
expected to have no significant antibacterial effect.
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